Search Results

Kane Biotech Inc. announces that it has entered into a worldwide license agreement with I-MED Pharma Inc. (“I-MED Pharma” or “I-MED”) for the DispersinB ® technology.

Enlyte and its Board of Directors have made the strategic decision to transfer its Independent Medical Examination (IME) business and more than 350 employees from Enlyte to the creation of a new, stand-alone IME company, Emperion, Inc.

Immunome, Inc. today announced that it will present preclinical data for IM-3050, the company’s lead lutetium-177 radioligand therapy (RLT) targeting fibroblast activation protein (FAP).

Theratechnologies Inc today announced that the Company has filed a supplemental Biologics License Application (sBLA) for an intramuscular (IM) method of administration for the maintenance dose of Trogarzo® (ibalizumab-uiyk) to the United States Food and Drug Administration (FDA) for review.

Medigene AG announced that the Company has been issued a patent by the European Patent Office protecting its inducible Medigene T cell receptor technology, which contains a control mechanism to regulate efficacy and improve safety of its T cell receptor engineered T cell therapies.

ImmunAbs, a leading clinical-stage biotechnology company focused on developing novel antibody therapeutics, announced the successful completion of the Phase 1 clinical trial for IM-101.

Arbutus Biopharma Corporation announced new data from its Phase 2a clinical trial IM-PROVE I showing that imdusiran, the Company’s RNAi therapeutic, and 24 weeks of pegylated interferon alfa-2α, a standard-of-care immunomodulator, added to ongoing nucleoside analogue therapy, reduced HBsAg levels and led to sustained HBsAg loss in some patients with cHBV during and after treatment.